The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 276 participants.

Also called NCT06236022

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 276 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06236022
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06236022. Randomized; no masking; primary purpose treatment. Start 2024-01-01 (actual); primary completion 2028-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
Acronym
SDCMK
Condition
Dilated Cardiomyopathy
Condition
Kaposi's Sarcoma-Associated Herpesvirus Infection
Intervention (Drug)
Sirolimus
Lead sponsor
Tongji Hospital (class: other)
Collaborator
Wuhan Central Hospital (class: other)
Collaborator
Wuhan Fourth Hospital (class: other)
Collaborator
Wuhan University (class: other)

Record details

Record id
cardio:ct-nct06236022
Content hash
0bb226ea786b5a3d217d1df9d1136055be27033cf43d4bdf7d8a013f2364db22